Microbiome

Virtual event

Microbiome

Virtual event

This event is co-hosted by biocrates and Everlife Research Instruments

Quantitative metabolomics| Powering the next generation of precision medicine

June 17, 2025 | 03:00 – 04:30 pm MYT | 09:00 – 10:30 am CET
Virtual event on ZOOM

Join us for an insightful webinar exploring how quantitative metabolomics is advancing precision medicine. Discover how this powerful approach enables large-scale studies in population health, and learn how it intersects with microbiome research to reveal the host’s metabolic response. Our experts will share real-world applications across diverse sample types, showcasing how microbial metabolites and host-microbiome interactions can be studied using targeted metabolomics.
Metabolomics is the most relevant tool to answer the multidimensional questions of system biology, providing quantitative, standardized, and quality-controlled assays that guarantee robust and reproducible results essential for clinical research.

 

Program overview

Globe

June 17, 2025
03:00 pm MYT | 09:00 am CEST
Virtual on ZOOM

Moderation and welcome

Dr. Tintelnot

Charleen Choo

Senior Sales Manager
Research Instruments Sdn Bhd
Malaysia

Speakers

Alice Limonciel

Alice Limonciel, Ph.D.

Chief Scientific Officer
biocrates life sciences ag | Austria

 

Metabolomics meets microbiome - Investigating host response with quantitative metabolomics

Besides directly measuring microbial metabolites, quantitative metabolomics enables the investigation of the effects of the microbiome on the broader metabolic picture of the host. In my talk, I will present examples of applications of metabolomics in various sample matrices and how to use this powerful tool to study the effects of the microbiome on the host.

Dr. Tintelnot

Carmen Ludwig-Papst, Ph.D.

Director Business Development
biocrates life sciences ag

Bridging cohorts and clinics: FAIR metabolomics for data-driven precision healthcare

This presentation outlines biocrates’ standardized, quantitative metabolomics solutions for large-scale and population-based studies. Emphasizing reproducibility, scalability, and compliance with FAIR data principles, biocrates technology enables a robust and broad profiling method across diverse cohorts and laboratories. By supporting data harmonization and integration, biocrates facilitates cross-study collaborations. Proven applications span multiple diseases, with use cases in cancer and cardiometabolic research. The approach integrates genomics and metabolomics (mGWAS) to reveal functional links between genetic variants and disease phenotypes, accelerating biomarker discovery and translational multi-omics research. We highlight its potential to advance precision diagnostics, therapeutic stratification, and data-driven clinical decision-making.

 

 

Gerner

Manuel Kratzke, Ph.D.

Senior Specialist | Applications Support
biocrates life sciences ag

Standardized metabolomics kits for quantitative and reproducible results

Kit workflow in the laboratory and the WebIDQ™ software

Metabolomics is the most relevant tool to answer the multidimensional questions of system biology. From just a few microliters of sample material, the phenotype of an individual can be uncovered. Quantitative, standardized, and quality-controlled targeted metabolomics assays guarantee robust and reproducible results that are the cornerstones of all clinical research.
biocrates kit technology offers a streamlined, high-throughput solution for quantitative metabolomics, delivering highly reproducible metabolomics data. In this presentation, we provide insights into the underlying technology and chemistry.
During this talk, we introduce our streamlined kit technology alongside WebIDQ, the companion software designed for an easy and user-friendly workflow. WebIDQ supports plate layout registration, sample analysis, quantification, data quality assessment, normalization, and export for statistical evaluation.
A brief live demonstration of WebIDQ’s key features will showcase how it simplifies metabolomics data processing.